Table 2.
Clinical trials evaluating the effects of the MeDiet on PD.
| Typology of the Study | Country | Period of Follow Up | Individuals Involved | Dietary Pattern | Results | Ref |
|---|---|---|---|---|---|---|
| Longitudinal | USA | 16 years | 49,692 + 81,676 (2 cohorts) | MeDiet-related | MeDiet-related diet protects against PD onset | [34] |
| Longitudinal | Sweden | 20 years | 47,128 | MeDiet | MeDiet reduces PD risk | [35] |
| Longitudinal | USA | 4.6 years | 706 | MIND; DASH; MeDiet | MIND reduces PD risk MIND and MeDiet slow PD progression |
[37] |
| Case-control | USA | 257 PD + 198 controls | MeDiet | MeDiet reduces PD risk | [38] | |
| Cross-sectional | Canada | 167 PD + 119 controls | MIND MeDiet | MIND and MeDiet protect against PD onset | [27] | |
| Cross-sectional | USA | 1053 PD | MeDiet-related | MeDiet-related foods slow PD progression | [39] | |
| Randomized clinical trial | Iran | 10 weeks | 80 PD | MeDiet | MeDiet improves both cognitive functions and locomotor performance in PD patients | [40] |
| Cross-sectional | Greece | 1731 | MeDiet | MeDiet protects against prodromal PD symptoms | [42] | |
| Longitudinal | USA | 16 years | 47,679 | MeDiet-related | MeDiet-related protects against prodromal PD symptoms | [43] |
| Randomized clinical trial | USA | 8 weeks | 52 PD | MeDiet | MeDiet improves constipation symptoms in PD patients | [22] |
| Single-arm clinical trial | USA | 5 weeks | 8 PD + 8 controls | MeDiet | MeDiet improves constipation symptoms in PD patients | [44] |